Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Centogene NV's Revenue for the
six
months ended in Dec. 2023 was $26.08 Mil. Centogene NV's average Accounts Receivable for the
six
months ended in Dec. 2023 was $18.87 Mil.
Hence, Centogene NV's Receivables Turnover for the
six
months ended in Dec. 2023 was 1.38.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Centogene NV Receivables Turnover Related Terms
Centogene NV Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Centogene NV's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTGF vs ISPC, CHEK, FUNI: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Centogene NV's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centogene NV Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Centogene NV's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centogene NV (CNTGF) has a Receivables Turnover of 1.38 as of Dec. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Centogene NV and its competitors.
Is Centogene NV's Receivables Turnover too high?
Centogene NV's current Receivables Turnover is 1.38. The Medical Diagnostics & Research industry median Receivables Turnover is 5.37. Centogene NV's value of 1.38 is 74.3% below this industry median. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's Receivables Turnover compare to ISPC and CHEK?
Centogene NV's Receivables Turnover of 1.38 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Receivables Turnover is 5.37. Centogene NV's value of 1.38 is 74.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.37, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Centogene NV's current Receivables Turnover of 1.38 is 74.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Centogene NV and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centogene NV's current Receivables Turnover is 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current Receivables Turnover of 1.38. The current Receivables Turnover is 1.38 and 74.3% below the Medical Diagnostics & Research industry median of 5.37. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Centogene NV (CNTGF), the current Receivables Turnover is 1.38 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score
Get the complete analysis for CNTGF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTGF has been successfully added to your 
